Company* |
Company* |
Product | Terms/Details (Date) |
| |||
Angel |
Nautilus Biotech* (France) |
Angel will manufacture Nautilus' interferon alpha drug Belerofon for Phase I trials |
Terms of the deal were not disclosed (12/6) |
Argenta |
TTP LabTech Ltd.* (UK) |
They launched a high-content assay development and screening service |
The offering for drug discovery will be promoted by both companies (1/24) |
Artes |
Proteo Biotech AG* (Germany) |
Artes will manufacture Proteo's Elafin, a product for cardiovascular conditions |
Artes licensed use of the yeast strain Hansenula polymorpha for use as an expression system (12/6) |
ArtisOptimus |
Taconic Farms Inc.* |
Deal to bring a collection of primary mouse embryonic fibroblasts to the research community |
ArtisOptimus will produce and distribute MEFs made from knockout mouse models to which Taconic holds exclusive rights; ArtisOptimus also licensed specific models (2/9) |
Biogen Idec |
Tanox Inc. (TNOX) |
Tanox leased a biologics equipment and furniture and fixtures; the manufacturing facility in San Diego and acquired certain assets to expand antibody production capacity |
Tanox is paying $5.5M for manufacturing lease runs through October 2011, with two five-year extension options (12/15) |
Cobra Bio- |
Oncolytics Biotech Inc. (Canada; ONCY) |
Extended deal under which Cobra will manufacture and supply Reolysin |
The manufacturing deal on the human reo- virus-based product is worth more than $1.4M to Cobra in 2005 (2/8) |
GenOway SA* |
Charles River Laboratories Inc. (NYSE:CRL) |
Collaboration to supply genetically modified research models in Europe |
Three-year deal under which Charles River will market and promote GenOway products to its European Transgenic Services customers (11/23) |
Illumina Inc. |
Invitrogen Corp. (IVGN) |
Deal to expand Illumina's Oligator DNA synthesis tech- nology and combine it with Invitrogen's marketing expertise |
Invitrogen will invest $3.4M in Illumina's San Diego facility, and begin taking over marketing responsibilities (12/20) |
Inyx Inc. |
NovaDel Pharma Inc. (AMEX:NVD) |
Five-year deal under which Inyx will produce NovaDel's nitroglycerin lingual spray |
The manufacturing contract is exclusive the first five years and nonexclusive the following five years (11/23) |
LION |
BioBase GmbH* (Germany) |
Collaboration to integrate BioBase's network content into LION's software products |
Terms of the deal were not disclosed (2/10) |
Stratagene |
Affymetrix Inc. (AFFX) |
Stratagene will provide Affymetrix customers with new software solutions for GeneChip data analysis |
Stratagene will develop a statistical analysis solution of Affymetrix gene expression microarrays under the nonexclusive deal (2/7) |
SuperArray |
Eurogentec SA* (Belgium) |
They entered a deal on Super- Array's cDNA GEArray DNA microarray platform |
Eurogentec got rights to repackage the products and sell them in Europe (11/22) |
Tm Bioscience |
Gamidor Diagnostics* (Israel) |
Gamidor will distrubute the Tag-It menu of genetic tests in Israel for three years |
The exclusive distribution deal can be extended annually; terms of the deal were not disclosed (11/29) |
| |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. |